Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group

European Journal of Cancer

Volumn 49, Issue 10, 2013, Pages 2384-2391

  Goldsby, Robert E ^a   Fan, Timothy M ^b   Villaluna, Doojduen ^c   Wagner, Lars M ^d   Isakoff, Michael S ^e   Meyer, James ^f   Lor Randall, R ^g   Lee, Sharon ^a   Kim, Grace ^a   Bernstein, Mark ^h   Gorlick, Richard ⁱ   Krailo, Mark ^j   Marina, Neyssa ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e Farmington   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^h IWK HEALTH CENTRE   (Canada)

ⁱ MONTEFIORE MEDICAL CENTER   (United States)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Chemotherapy; Metastatic osteosarcoma; Zoledronic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; CREATININE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; MESNA; METHOTREXATE; RAZOXANE; ZOLEDRONIC ACID;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE METASTASIS; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER GROWTH; CHILD; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG SAFETY; EVENT FREE SURVIVAL; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFANT; JAW OSTEONECROSIS; LIMB PAIN; LUNG BIOPSY; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; PERIPHERAL EDEMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT PLANNING;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EDEMA; EXTREMITIES; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; IMIDAZOLES; KAPLAN-MEIER ESTIMATE; MALE; MUCOSITIS; NEOPLASM METASTASIS; OSTEOSARCOMA; PAIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878395719     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.03.018     Document Type: Article

References (41)

1. P.A. Voute, R.L. Souhami, and M. Nooij A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI) Ann Oncol 10 10 1999 1211 1218
2. S.R. Patel, N. Papadopolous, and A.K. Raymond A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis Cancer 101 1 2004 156 163
3. L. Kager, A. Zoubek, and U. Potschger Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols J Clin Oncol 21 10 2003 2011 2018
4. P.A. Meyers, G. Heller, and J.H. Healey Osteogenic sarcoma with clinically detectable metastasis at initial presentation J Clin Oncol 11 3 1993 449 453
5. W.H. Meyer, C.B. Pratt, and C.A. Poquette Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial J Clin Oncol 19 1 2001 171 182
6. M.B. Harris, P. Gieser, and A.M. Goorin Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study J Clin Oncol 16 11 1998 3641 3648
7. A.M. Goorin, M.B. Harris, and M. Bernstein Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial J Clin Oncol 20 2 2002 426 433
8. G. Bacci, A. Briccoli, and S. Ferrari Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide Oncol Rep 7 2 2000 339 346
9. R. Gorlick, P. Anderson, and I. Andrulis Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary Clin Cancer Res 9 15 2003 5442 5453
10. H.T. Hatoum, S.J. Lin, M.R. Smith, V. Barghout, and A. Lipton Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database Cancer 113 6 2008 1438 1445
11. A. Lipton, M. Zheng, and J. Seaman Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma Cancer 98 5 2003 962 969
12. L.S. Rosen, D. Gordon, and M. Kaminski Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial Cancer 98 8 2003 1735 1744
13. L.S. Rosen, D. Gordon, and N.S. Tchekmedyian Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial Cancer 100 12 2004 2613 2621
14. F. Saad, D.M. Gleason, and R. Murray Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 11 2004 879 882
15. C.R. Dass, and P.F. Choong Zoledronic acid inhibits osteosarcoma growth in an orthotopic model Mol Cancer Ther 6 12 Pt 1 2007 3263 3270
16. A. Labrinidis, S. Hay, V. Liapis, D.M. Findlay, and A. Evdokiou Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model Int J Cancer 127 2 2010 345 354
17. A. Labrinidis, S. Hay, V. Liapis, V. Ponomarev, D.M. Findlay, and A. Evdokiou Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model Clin Cancer Res 15 10 2009 3451 3461
18. B. Ory, M.F. Heymann, A. Kamijo, F. Gouin, D. Heymann, and F. Redini Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice Cancer 104 11 2005 2522 2529
19. J. Sonnemann, V. Eckervogt, B. Truckenbrod, J. Boos, W. Winkelmann, and F. van Valen The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro Anticancer Drugs 12 5 2001 459 465
20. A. Evdokiou, A. Labrinidis, S. Bouralexis, S. Hay, and D.M. Findlay Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis Bone 33 2 2003 216 228
21. N. Horie, H. Murata, and S. Kimura Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma Br J Cancer 96 2 2007 255 261
22. D. Heymann, B. Ory, and F. Blanchard Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma Bone 37 1 2005 74 86
23. A. Bamias, E. Kastritis, and C. Bamia Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors J Clin Oncol 23 34 2005 8580 8587
24. M.A. Perazella, and G.S. Markowitz Bisphosphonate nephrotoxicity Kidney Int 74 11 2008 1385 1393
25. J.D. Kalbfleisch, and R.L. Prentice The statistical analysis of failure time data 2nd ed. 2002 John Wiley and Sons, Inc. New York
26. N.L. Seibel, M. Krailo, and Z. Chen Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943 Cancer 109 8 2007 1646 1653
27. A.J. Chou, E.S. Kleinerman, and M.D. Krailo Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group Cancer 115 22 2009 5339 5348
28. J.R. Berenson Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials Semin Oncol 28 2 Suppl. 6 2001 25 34
29. H.V. Russell, S.G. Groshen, and T. Ara A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study Pediatr Blood Cancer 57 2 2011 275 282
30. J.R. Green Bisphosphonates: preclinical review Oncologist 9 Suppl. 4 2004 3 13
31. S.P. Luckman, D.E. Hughes, F.P. Coxon, R. Graham, G. Russell, and M.J. Rogers Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras J Bone Miner Res 13 4 1998 581 589
32. A. Ibrahim, N. Scher, and G. Williams Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases Clin Cancer Res 9 7 2003 2394 2399
33. J.M. Wilkinson, A.C. Eagleton, I. Stockley, N.F. Peel, A.J. Hamer, and R. Eastell Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial J Orthop Res 23 1 2005 1 8
34. M.B. Mintz, R. Sowers, and K.M. Brown An expression signature classifies chemotherapy-resistant pediatric osteosarcoma Cancer Res 65 5 2005 1748 1754
35. P.A. Meyers, J.H. Healey, and A.J. Chou Addition of pamidronate to chemotherapy for the treatment of osteosarcoma Cancer 117 8 2011 1736 1744
36. K.J. August, A. Dalton, and H.M. Katzenstein The use of zoledronic acid in pediatric cancer patients Pediatr Blood Cancer 56 4 2011 610 614
37. S. Battaglia, S. Dumoucel, and J. Chesneau Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient J Bone Miner Res 26 10 2011 2439 2451
38. T. Hiraga, T. Ninomiya, A. Hosoya, and H. Nakamura Administration of the bisphosphonate zoledronic acid during tooth development inhibits tooth eruption and formation and induces dental abnormalities in rats Calcif Tissue Int 86 6 2010 502 510
39. R.E. Coleman, P. Major, and A. Lipton Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid J Clin Oncol 23 22 2005 4925 4935
40. V. Hirsh, P.P. Major, and A. Lipton Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity J Thorac Oncol 3 3 2008 228 236
41. A. Lipton, R. Cook, and F. Saad Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid Cancer 113 1 2008 193 201